Trials / Recruiting
RecruitingNCT05906576
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
Detailed description
This is a prospective, multicenter registry study in Chinese pediatric Crohn's disease patients. A total of 30 subjects were planned to be enrolled and treated with Infliximab. Subjects were observed for 102 weeks after administration to evaluate the clinical efficacy and safety of infliximab in the treatment of children with Crohn's disease in a real diagnostic setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Infliximab | Infliximab in the treatment of Crohn's disease in children |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2026-11-01
- Completion
- 2027-02-01
- First posted
- 2023-06-18
- Last updated
- 2025-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05906576. Inclusion in this directory is not an endorsement.